Navigation Links
Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:1/29/2008

WESTMINSTER, Colo., Jan. 29 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that members of the Company's senior management will present a corporate overview at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in New York.

The Company's presentation will take place at 11:00 a.m. (Eastern) on Tuesday, February 5, 2008. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through February 22, 2008.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins lymphoma (NHL). For additional information, please visit the Company's website at

SOURCE Allos Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
3. Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The California Healthcare ... organization representing leading California academic institutions, biotechnology, medical ... US today released a report revealing that ... growth. The trend shows a 4 percent increase ... Biomedical Industry Report indicates that, while biopharmaceutical ...
(Date:11/21/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on the ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/21/2014)... (TSXV: BRM) ("Biorem" or "the Company") today announced results for the ... complete 2014 third quarter financial statements and MD&A have been filed ... September 30, , Nine-months ended September 30, ( ... , 2013 , 2014 , 2013 ... 6,715 , 14,476 Gross profit , 521 ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – ... a professor in the Regulatory Biology Laboratory at the Salk ... points to an “off switch” for drug resistance in cancer. ... local research is making a global impact in the fight ... join host Cheryl K. Goodman, CEO of Social Global Mobile ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... SAN FRANCISCO, March 27 Nile Therapeutics, Inc. ... development of novel therapeutics for heart failure patients, announced today ... (IND) application materials that Nile submitted to the U.S. Food ... Company,s Phase IIb clinical trial with CD-NP for the treatment ...
... (Nasdaq: WCRX ) announced today that its ... Drug Application for WC 3016, a low-dose oral contraceptive, ... Warner Chilcott , Warner Chilcott is a ... healthcare and dermatology segments of the U.S. pharmaceuticals market. ...
... Companies Will Offer a Personal Health Record ... Keep ,First Puppy, Healthy and Kissably Sweet ... MMR Information Systems, Inc. (OTC Bulletin ... subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") provides consumer-controlled ...
Cached Biology Technology:Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure 2Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive 2Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive 3MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 2MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 3MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 4
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... 4, 2014) – A majority of Madagascar,s 101 species ... have serious consequences for the rainforests they call home. ... positive impacts lemurs can have on rainforest tree populations, ... could have on the region,s rich biodiversity. , A ... eaten by lemurs. Lemurs in turn disperse the ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... 250 million year-old species of large, meat-eating amphibians ... McGill University. Their findings published in today's issue ... carnivores from the Republic of Niger in West ... in this area," says McGill paleontologist, and co-author, ...
... relationship between a wasp species and a newly ... light on how bacteria can be successfully utilized ... microbes. In the new work, researchers show that ... Streptomyces bacteria in unique structures within its antennae ...
... found only in germ-line cells results in infertility in ... from researchers at the University of Pennsylvania School of ... Penn's Center for Research in Reproduction and Women's Health, ... to a new type of contraceptive for both men ...
Cached Biology News:Symbiotic bacteria protect hunting wasps from fungal infestation 2Of mice and men's (and women's) contraceptives 2
... used to quantitate double-stranded DNA (dsDNA) in solution, ... With this kit, DNA is stained with Hoechst ... VersaFluor or other fluorometer. The kit quantitates dsDNA ... to 5 micrograms per ml and contains Hoechst ...
... stimulating factors for assays of mouse hematopoietic ... fetal liver. Suitable for the growth ... when added to methylcellulose at a final ... Will also support growth of mouse ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
...
Biology Products: